Laimei Pharmaceuticals announced abnormal fluctuations in stock trading. Up to now, nano-carbon-iron combined radiotherapy is still in the phase II clinical trial stage. Further, it is still necessary to proceed with core aspects such as applying for breakthrough treatment certification, or conducting phase III clinical trials and applying for drug marketing approval. There are major uncertainties in all of the above core aspects. There are risks such as the results of the phase II clinical trial falling short of expectations, not being able to apply for or be approved for breakthrough treatment certification, not being able to conduct or complete the phase III clinical trial, not being able to submit or obtain approval for an NDA, and delays in the review and approval process. Drug research and development is a long-term process. It is expected that it will not have a significant impact on the company's business performance in the short term, from early research and development, clinical trial execution to marketing approval, and the process is easily affected by various uncertainties. There is uncertainty about whether it can be successfully approved for marketing and approval time.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.